Stocks and Investing
Stocks and Investing
Mon, May 13, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Sykes Maintained (CDNA) at Strong Buy with Increased Target to $14 on, May 13th, 2024
Matthew Sykes of Goldman Sachs, Maintained "CareDx, Inc" (CDNA) at Strong Buy with Increased Target from $10 to $14 on, May 13th, 2024.
Matthew has made no other calls on CDNA in the last 4 months.
There are 2 other peers that have a rating on CDNA. Out of the 2 peers that are also analyzing CDNA, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Matthew
- Connor Chamberlain of "Craig-Hallum" Reiterated at Strong Buy and Held Target at $15 on, Thursday, May 9th, 2024
- Alexander Nowak of "Craig-Hallum" Upgraded from Hold to Strong Buy and Increased Target to $15 on, Wednesday, May 1st, 2024
Contributing Sources